Alembic Pharmaceuticals announced that it has successfully completed the United States Food and Drug Administration (USFDA) inspection for its Oral Solid Formulation Facility (F-I) located at Panelav.
This was a scheduled GMP inspection and was successfully completed without any Form 483 observation. The inspection was conducted from July 17 to 26, 2024.